摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Pyrazino [1, 2-a] indole | 245-44-3

中文名称
——
中文别名
——
英文名称
Pyrazino [1, 2-a] indole
英文别名
PYRAZINO [1,2-A] INDOLE;Pyrazino[1,2-a] indole;pyrazino[1,2-a]indole;indolo[1,2-A]pyrazin
Pyrazino [1, 2-a] indole化学式
CAS
245-44-3
化学式
C11H8N2
mdl
——
分子量
168.198
InChiKey
GCZDLZHMAMLSJF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    17.3
  • 氢给体数:
    0
  • 氢受体数:
    1

SDS

SDS:94750df60aeee58379fa7e6e0ef72c4e
查看

反应信息

  • 作为产物:
    描述:
    2-benzylpyrazine N1-oxide 以44%的产率得到
    参考文献:
    名称:
    OHSAWA, AKIO;KAWAGUCHI, TAKAYUKI;IGETA, HIROSHI, SYNTHESIS, BRD, 1983, N 12, 1037-1040
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents
    申请人:Wunberg Tobias
    公开号:US20070185121A1
    公开(公告)日:2007-08-09
    The invention relates to heterocyclyl-substituted dihydroquinazolines of formula (I), to processes for their preparation, to medicaments containing them, and to methods for the treatment and/or prophylaxis of diseases, in particular, for use as anti-viral agents, in particular, against cytomegaloviruses.
    这项发明涉及公式(I)的杂环基取代的二氢喹唑啉,以及它们的制备方法、含有它们的药物,以及用于治疗和/或预防疾病的方法,特别是作为抗病毒剂,特别是针对巨细胞病毒。
  • [EN] PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE<br/>[FR] PIPÉRAZINO[1,2-A]INDOL-1-ONES ET [1,4]DIAZÉPINO[1,2-A]INDOL-1-ONE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2014023674A1
    公开(公告)日:2014-02-13
    The present invention relates to compounds of general formula (I), wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen or cyano; R2 is hydrogen, lower alkyl or lower alkyl substituted by halogen; R3 is phenyl, benzo[1,3]dioxolyl, 2,3-dihydro-benzofuran-5-yl or a 5- and 6-membered heteroaryl, wherein phenyl and the 5- and 6-membered heteroaryl groups may be substituted by one or more substituents, selected from cyano, nitro, amino and lower di-alkylamino, lower alkyl sulfonyl, lower alkoxy, lower alkoxy substituted by halogen, halogen, lower alkyl, lower alkyl substituted by halogen or lower alkyl substituted by hydroxyl; X is -CH(lower alkyl)-, -CH2-, -CH2CH2- or –CH(lower alkyl)CH2-; R is hydrogen or lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.
    本发明涉及一般式(I)的化合物,其中R1是氢、卤素、较低烷基、较低烷氧基、被卤素或基取代的较低烷氧基;R2是氢、较低烷基或被卤素取代的较低烷基;R3是苯基、苯并[1,3]二噁英基、2,3-二氢-苯并呋喃-5-基或5-和6-成员杂芳基,其中苯基和5-和6-成员杂芳基可能被基、硝基、基和较低二烷基基、较低烷基磺酰基、较低烷氧基、被卤素取代的较低烷氧基、卤素、较低烷基、被卤素取代的较低烷基或被羟基取代的较低烷基等一个或多个取代基取代;X是-CH(较低烷基)-、-CH2-、- -或-CH(较低烷基) -;R是氢或较低烷基;n是1或2;或是药学上可接受的酸盐,或是外消旋混合物,或是其对映体和/或光学异构体。这些化合物可用于治疗精神分裂症、强迫性人格障碍、重度抑郁症、躁郁症、焦虑障碍、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩性侧索硬化、多发性硬化、亨廷顿病、中风、放射治疗、慢性压力、对神经活性药物的滥用,如酒精、阿片类药物、甲基苯丙胺、芬西克林和可卡因
  • Pirazino(aza)indole derivatives
    申请人:VERNALIS RESEARCH LIMITED
    公开号:US20040092525A1
    公开(公告)日:2004-05-13
    Chemical compounds of formula (I): 1 and pharmaceutically acceptable salts and addition compounds and prodrugs thereof are useful in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea.
    化学式(I)的化合物1及其药学上可接受的盐、加合物和前药在治疗中具有用处,特别是用于治疗中枢神经系统疾病;中枢神经系统损伤;心血管疾病;胃肠道疾病;尿崩症和睡眠呼吸暂停症。
  • Pirazino(AZA) indole derivatives
    申请人:Adams Reginald David
    公开号:US20060160816A1
    公开(公告)日:2006-07-20
    Chemical compounds of formula (I): and pharmaceutically acceptable salts and addition compounds and prodrugs thereof are useful in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea.
    化学式为(I)的化合物,以及其药学上可接受的盐和加合物以及其前药,在治疗中具有用处,特别是用于治疗中枢神经系统疾病; 中枢神经系统损伤; 心血管疾病; 胃肠道疾病; 尿崩症和睡眠呼吸暂停症。
  • Pirazino(AZA)indole derivatives
    申请人:VERNALIS RESEARCH LIMITED
    公开号:US20040039200A1
    公开(公告)日:2004-02-26
    Chemical compounds of formula (I): 1 and pharmaceutically acceptable salts and addition compounds and prodrugs thereof are useful in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea.
    化学式(I)的化合物1及其药学上可接受的盐、加合物和前药在治疗中非常有用,特别是用于治疗中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠道疾病、尿崩症和睡眠呼吸暂停。
查看更多

同类化合物

舒立克隆 次黄嘌呤-[2,8-3H] 吡唑并[1,5-a]吡咯并[2,1-C]吡嗪 吡咯并[1,2-a]噻吩并[2,3-e]吡嗪 吡咯并[1,2-a]吡嗪-8-甲醛 吡咯并[1,2-a]吡嗪-6-甲醛(9CI) 吡咯并[1,2-a]吡嗪-3-羧酸乙酯 吡咯并[1,2-a]吡嗪-3-羧酸 吡咯并[1,2-a]吡嗪,4-乙基-(9CI) 吡咯并[1,2-a]吡嗪 吡咯并[1,2-A]吡嗪-6-甲醇 右佐匹克隆 佐匹克隆氧化物 佐匹克隆杂质3 佐匹克隆杂质1 佐匹克隆 二羰雙吡咯 乙酰氨基-6-吡咯并[1,2-a]噻吩并[2,3-e]吡嗪 乌帕替尼 乌帕替尼 N-甲基-5-溴-4,7-二氮杂吲哚 N-去甲基佐匹克隆 7-碘-5H-吡咯并[2,3-b]吡嗪 7-甲基-6,8-二(甲硫基)吡咯并[1,2-a]吡嗪 7-溴吡咯并[1,2-a]吡嗪-1(2H)-酮 7-氯甲基氧基-羰基氧基-6-(5-氯吡啶-2-基)-6,7-二氢-5H-吡咯并[3,4-b]吡嗪-5-酮 6-甲基-吡咯并[1,2-a]吡嗪 6-溴吡咯并[1,2-A]吡嗪-1(2H)-酮 6-溴吡咯[1,2-A]吡嗪-3-羧酸乙酯 6-(7-氯-1,8-萘啶-2-基)-6,7-二氢-7-羟基-5H-吡咯并[3,4-b]吡嗪-5-酮 6-(7-氯-1,8-萘啶-2-基)-2,3,6,7-四氢-7-羟基-5H-1,4-二噻英并[2,3-c]吡咯-5-酮 6-(5-氯-吡啶-2-基)-7-苯氧基羰基氧基-6,7-二氢-吡咯并3,4-b吡嗪-5-酮 6-(5-氯-2-吡啶基)-6,7-二氢-7-羟基-5H-吡咯并[3,4-b]吡嗪-5-酮 6-(5-氯-1,8-萘啶-2-基)-2,3,6,7-四氢-7-氧代-5H-1,4-二噻英并[2,3-c]吡咯-5-基4-甲基哌嗪-1-羧酸酯 6,7,8,9-四氢吡嗪并[1,2-A]吲哚-1(2H)-酮 5H-吡嗪并[2,3-b]吲哚 5H-吡咯并[2,3-b]吡嗪-7-羧醛 5H-吡咯并[2,3-b]吡嗪-2-羧酸甲酯 5H-吡咯[2,3-B]吡嗪-7-乙酸 5-甲基-5H-吡咯并[2,3-b]吡嗪-7-羧酸甲酯 5-溴-4,7-二氮杂吲哚 5-氯-2-(7-氯-1,8-萘啶-2-基)-3-羟基异吲哚啉-1-酮 5-氢吡咯并[2,3-b]吡嗪-7-甲酸 4,7-二氮杂吲哚 3-羟基-2-(7-甲氧基-[1,8]萘啶-2-基)-2,3-二氢-异吲哚-1-酮 3-甲基吡咯并[1,2-a]吡嗪-1(2H)-酮 3-溴-5H-吡咯并[2,3-b]吡嗪 3-溴-4,7-二氮杂吲哚 3-氯-5H-吡咯并[2,3-b]吡嗪 3,6,7-三甲基吡咯并[1,2-a]吡嗪